Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, ...
The FDA-approved antiviral Paxlovid is underused for high-risk COVID-19 patients, despite its efficacy in preventing severe illness.
Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and better-than-expected demand for its COVID ...
Our focus is critical as we approach meaningful inflection points with the potential to develop the first anti-viral ...
H5N1 has been detected in over 9,000 wild birds, 90 million poultry and in dairy cattle. A recent human case in Texas has ...
Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales of its COVID ...
Pfizer lifted its annual profit forecast on Wednesday, and reported first-quarter results that topped Wall Street estimates ...
May 1 - Pfizer lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its COVID antiviral treatment and strong demand for pneumonia vaccine, sending its ...
boosted by cost cutting efforts and stronger-than-expected sales of its COVID antiviral treatment. Sales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion ...
Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year over year, beating the consensus of $0.54.